AIM: The aim of the study was to investigate the impact of early response (ER) to hepatic arterial infusion chemotherapy (HAIC) on outcomes of @entity1 with @entity157 ( @entity157 ) complicated with major @entity715 ( @entity715 ). METHODS: Thirty-nine @entity1 receiving HAIC with low-dose @entity900 , @entity1487 ( @entity1487 ), and @entity4181 were enrolled. One course of HAIC consisted of 5 days of treatment and 2 days rest per week for 4 consecutive weeks. ER was categorized as complete response, partial response, or minor response and was determined by World Health Organization criteria with dynamic computed tomography findings performed within 1 week after the first course of HAIC. RESULTS: Thirteen (33%) @entity1 achieved an ER. Twelve (92.3%) of these 13 ER @entity1 achieved a higher overall response than all but one (3.8%) of the 26 non-early responders (NERs) (p<0.001). ER was the exclusive independent favorable factor for survival (p=0.003). Downstaging of @entity5 was noted in 76.9% of ERs, and these @entity1 could proceed to locoregional therapies. ER @entity1 subsequently had a higher 1-year survival (76.9% vs. 3.8%, p<0.001) and 6-month progression-free survival (PFS) (84.6% vs. 15.4%, p<0.001) than those for NERs. Only 8% of @entity1 experienced grade 3 or higher @entity137 during the first 4-week course of HAIC. CONCLUSIONS: HAIC can yield a satisfactory ER for advanced @entity157 with @entity715 . Moreover, achievement of ER after HAIC in advanced @entity157 with @entity715 is strongly associated with better overall survival and PFS.

Hepatic Arterial Infusion Chemotherapy for Advanced XXXX with @entity715 : Impact of Early Response to 4 Weeks of Treatment.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'advanced hepatocellular carcinoma'] @entity715 :: ('MESH:D013927', 'Disease') :: ['PVTT', 'portal vein tumor thrombosis'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5FU', '5-fluorouracil']
@entity157 :: (MESH:D006528,Disease) :: ['Hepatocellular Carcinoma']
